Oral physostigmine treatment of patients with Alzheimer's disease.

Twelve patients with Alzheimer's disease received 0.0, 0.5, 1.0, 1.5, and 2.0 mg of oral physostigmine every 2 hours for 3-5 days; symptoms after each dose were assessed with the Alzheimer's Disease Assessment Scale. Placebo and the dose associated with the least severe symptoms were then readministered for 3-5 days each. Of the 10 patients who completed the study, three showed clinically significant improvement on the highest physostigmine dose in both phases, four more were marginally improved in both phases, and three had inconsistent responses to physostigmine. Cortisol measures obtained during a sleep study suggest that patients whose symptoms improved on physostigmine were those in whom oral physostigmine enhanced central cholinergic activity.

[1]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[2]  M. Sugishita,et al.  Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[3]  L. Thal,et al.  Oral physostigmine and lecithin improve memory in Alzheimer disease , 1983, Annals of neurology.

[4]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[5]  D. Neary,et al.  Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease , 1983, Journal of neurochemistry.

[6]  R. Whelpton.  Analysis of plasma physostigmine concentrations by liquid chromatography. , 1983, Journal of chromatography.

[7]  J. S. Benton,et al.  Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients , 1982, Journal of the Neurological Sciences.

[8]  K. Davis,et al.  Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. , 1982, The American journal of psychiatry.

[9]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[10]  H. Weingartner,et al.  Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. , 1982, Biological psychiatry.

[11]  C. Caltagirone,et al.  Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. , 1982, The International journal of neuroscience.

[12]  J. Barchas,et al.  Neuroendocrine and neurochemical measurements in depression. , 1981, The American journal of psychiatry.

[13]  K. Davis,et al.  Partial reversal of anticholinergic amnesia by choline chloride. , 1981, Life sciences.

[14]  L. Thal,et al.  Choline chloride fails to improve cognition in Alzheimer's disease , 1981, Neurobiology of Aging.

[15]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[16]  L. Jarvik,et al.  Physostigmine and its effect on six patients with dementia. , 1981, The American journal of psychiatry.

[17]  M. Roth,et al.  SELECTIVE LOSS OF NEURONES OF ORIGIN OF ADRENERGIC PROJECTION TO CEREBRAL CORTEX (NUCLEUS LOCUS COERULEUS) IN SENILE DEMENTIA , 1981, The Lancet.

[18]  R. A. Pieter Kark,et al.  Double‐blind, triple‐crossover trial of low doses of oral physostigmine in inherited ataxias , 1981, Neurology.

[19]  T. Crow,et al.  Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease , 1981, British medical journal.

[20]  J. Ferguson,et al.  Physostigmine and Arecoline: Effects of Intravenous Infusions in Alzheimer Presenile Dementia , 1981, British Journal of Psychiatry.

[21]  R. Katzman.,et al.  Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa , 1980, Nature.

[22]  E. Caine.  Cholinomimetic treatment fails to improve memory disorders. , 1980, The New England journal of medicine.

[23]  K. Davis,et al.  Choline chloride effects on memory in the elderly , 1980, Neurobiology of Aging.

[24]  K. Davis,et al.  CKholinergic mechanisms and anterior pituitary hormone secretion. , 1980, Biological psychiatry.

[25]  D. Schmidt,et al.  Neuropharmacological consequences of choline administration , 1980, Brain Research.

[26]  D. Neary,et al.  GLUCOSE METABOLISM AND ACETYLCHOLINE SYNTHESIS IN RELATION TO NEURONAL ACTIVITY IN ALZHEIMER'S DISEASE , 1980, The Lancet.

[27]  R. Bartus.  Physostigmine and recent memory: effects in young and aged nonhuman primates. , 1979, Science.

[28]  K. Davis,et al.  Choline chloride treatment of memory deficits in the elderly. , 1979, The American journal of psychiatry.

[29]  J. Coyle,et al.  Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Harvey S. Levin,et al.  Effects of physostigmine and lecithin on memory in Alzheimer disease , 1979, Annals of neurology.

[31]  M. Swash,et al.  PHYSOSTIGMINE IN ALZHEIMER'S DISEASE , 1979, The Lancet.

[32]  K. Davis,et al.  Enhancement of memory by physostigmine. , 1979, The New England journal of medicine.

[33]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[34]  K. Davis,et al.  Physostigmine: improvement of long-term memory processes in normal humans. , 1978, Science.

[35]  Robert H. Perry,et al.  Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue , 1977, Journal of the Neurological Sciences.

[36]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[37]  D M Bowen,et al.  Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. , 1976, Brain : a journal of neurology.

[38]  R. Wurtman,et al.  Brain acetylcholine: control by dietary choline. , 1976, Science.

[39]  J Marshall,et al.  Cerebral blood flow in dementia. , 1975, Archives of neurology.

[40]  D. Drachman,et al.  Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.

[41]  D. Krieger,et al.  Circadian Pattern of Plasma 17-Hydroxycorticosteroid: Alteration by Anticholinergic Agents , 1967, Science.

[42]  M. Sim,et al.  ALZHEIMER'S DISEASE: ITS NATURAL HISTORY AND DIFFERENTIAL DIAGNOSIS , 1962, The Journal of nervous and mental disease.